Nanobiotix Sa Stock Current Asset
| NANO Stock | EUR 3.22 0.11 3.30% |
Nanobiotix SA fundamentals help investors to digest information that contributes to Nanobiotix's financial success or failures. It also enables traders to predict the movement of Nanobiotix Stock. The fundamental analysis module provides a way to measure Nanobiotix's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nanobiotix stock.
Nanobiotix |
Nanobiotix SA Company Current Asset Analysis
Nanobiotix's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Nanobiotix Current Asset | 23 M |
Most of Nanobiotix's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nanobiotix SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Nanobiotix SA has a Current Asset of 23 M. This is 98.93% lower than that of the Healthcare sector and 99.84% lower than that of the Drug Manufacturers - Major industry. The current asset for all France stocks is 99.75% higher than that of the company.
Nanobiotix Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nanobiotix's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nanobiotix could also be used in its relative valuation, which is a method of valuing Nanobiotix by comparing valuation metrics of similar companies.Nanobiotix is currently under evaluation in current asset category among its peers.
Nanobiotix Fundamentals
| Return On Equity | -1.99 | |||
| Return On Asset | -0.29 | |||
| Operating Margin | (17.96) % | |||
| Current Valuation | 111.08 M | |||
| Shares Outstanding | 34.88 M | |||
| Shares Owned By Insiders | 3.78 % | |||
| Shares Owned By Institutions | 25.56 % | |||
| Price To Earning | (12.17) X | |||
| Price To Book | 71.98 X | |||
| Price To Sales | 48.04 X | |||
| Revenue | 10 K | |||
| Gross Profit | 2.65 M | |||
| EBITDA | (44.85 M) | |||
| Net Income | (47 M) | |||
| Cash And Equivalents | 36.2 M | |||
| Cash Per Share | 1.85 X | |||
| Total Debt | 35.56 M | |||
| Debt To Equity | 144.00 % | |||
| Current Ratio | 3.68 X | |||
| Book Value Per Share | 0.05 X | |||
| Cash Flow From Operations | (29.87 M) | |||
| Earnings Per Share | (1.20) X | |||
| Target Price | 14.9 | |||
| Number Of Employees | 103 | |||
| Beta | 1.8 | |||
| Market Capitalization | 115.07 M | |||
| Total Asset | 101.77 M | |||
| Retained Earnings | (17 M) | |||
| Working Capital | 16 M | |||
| Current Asset | 23 M | |||
| Current Liabilities | 7 M | |||
| Z Score | 1.8 | |||
| Net Asset | 101.77 M |
About Nanobiotix Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nanobiotix SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nanobiotix using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nanobiotix SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Nanobiotix Stock
Nanobiotix financial ratios help investors to determine whether Nanobiotix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nanobiotix with respect to the benefits of owning Nanobiotix security.